+ Watch ONTY
on My Watchlist
Strong probability tecemotide succeeds in stage 3 trial-- which would push shares above the $4 dollar mark. Also, nice chance of Merck buyout before then, which would provide significant upside. Potential homerun in the making here.
Big upside with START2. $3+ valuation in near-term.
Cancer Bio. Hammered recently. Willing to buy here/ hold for the Ph III run up.
Waiting for Ph 3 stimuvax results...thinking stock may have bottomed.
Another stock getting ready to break out. This stock is undervalued right now, and it is prime for the picking. Get ready for shooting star.
Very compelling early data from phase II. Existing trial is continuing and data is expected late Q2. Very strong pipeline ahead of them. 1 small molecule with very good chemistry AND a more powerful version of the existing drug, this new drug is not partnered and its value will go up tremendously with the approval, if and when it happens.
Oncothyreon ONTY Rodman & Renshaw Mkt Outperform $10 (as of 4/26/11)
See slide 15 of yesterdays Needham conf. Absolutely amazing results.....Zero cancer growth.
Cancer drug in Phase 3
it has some "hidden" gems ready to be announced
Promising drugs don't deserve $100 million market caps.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions